<DOC>
	<DOCNO>NCT00916669</DOCNO>
	<brief_summary>The purpose research study see add enoxaparin sodium standard treatment chemotherapy drug cisplatin etoposide help treat extensive stage SCLC . Two different dos enoxaparin sodium study order determine one dose effective . Enoxaparin sodium ( Lovenox ) drug approve FDA help treat prevent blood clot . Results previous research study suggest add enoxaparin sodium standard treatment improved response treatment study participant various type cancer .</brief_summary>
	<brief_title>A Randomized Study Evaluate Effect Two Different Doses Enoxaparin Sodium Combination With Standard Chemotherapy Patients With Stage Small Cell Lung Cancer ( SCLC )</brief_title>
	<detailed_description>- Since one know study option best , participant randomize one three study treatment group . Group A receive cisplatin etoposide . Group B receive cisplatin etoposide plus low-dose enoxaparin sodium . Group C receive cisplatin etoposide plus high-dose enoxaparin sodium . - Study treatment divide chemotherapy post-chemotherapy period . All three group ( Group A , B C ) receive six 3-week cycle chemotherapy . Groups B C also receive daily enoxaparin sodium chemotherapy stage daily enoxaparin sodium 1 year chemotherapy . - Cisplatin etoposide give infusion 3-week cycle six cycle . Enoxaparin sodium give injection skin side abdomen . Participants instruct give injection .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Enoxaparin</mesh_term>
	<criteria>18 year age old Histologically cytologically document extensive disease small cell lung cancer . Only small cell histology eligible . Mixed histology eligible . Patients consider operable disease eligible Radiographic measurable disease RECIST criterion Life expectancy great 4 month ECOG Performance Status less equal 2 Patients must appropriate candidate standard combination cisplatin etoposide SCLC . There restriction radiotherapy No prior chemotherapy SCLC cancer Participants must meet hematological , renal hepatic function requirement outline protocol If brain bone metastases present time initial diagnosis , patient must complete radiation treatment least 2 week start study No active uncontrolled infection No serious illness medical condition opinion investigator would expect interfere subject 's ability receive study treatment comply study procedures New ( define 6 month less ) symptomatic thrombosis time enrollment Indication anticoagulant treatment mechanical heart valve , atrial fibrillation , previous VTE Contraindication know hypersensitivity LMWH unfractionated heparin ( UFH ) Active bleed disorder Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant breast feeding woman Individuals history different malignancy ineligible except follow circumstance . Individuals history malignancy eligible diseasefree least 5 year deem investigator low risk recurrence malignancy . Individuals follow cancer eligible diagnose treat within past 5 year ; cervical situ , basal cell squamous cell carcinoma skin HIVpositive individual combination antiretroviral therapy ineligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>SCLC</keyword>
	<keyword>enoxaparin sodium</keyword>
	<keyword>cisplatin</keyword>
	<keyword>etoposide</keyword>
</DOC>